Medicine and Health Sciences Commons^™

Blood-Based Molecular Biomarkers For Alzheimer's Disease, Henrik Zetterberg, Samantha C. Burnham

Research outputs 2014 to 2021

A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD …

Plasma Neurofilament Light Chain And Amyloid-Β Are Associated With The Kynurenine Pathway Metabolites In Preclinical Alzheimer's Disease, Pratishtha Chatterjee, Henrik Zetterberg, Kathryn Goozee, Chai K. Lim, Kelly R. Jacobs, Nicholas J. Ashton, Abdul Hye, Steve Pedrini, Hamid R. Sohrabi, Tejal Shah, Prita R. Asih, Preeti Dave, Kaikai Shen, Kevin Taddei, David B. Lovejoy, Gilles J. Guillemin, Kaj Blennow, Ralph N. Martins

Research outputs 2014 to 2021

BACKGROUND: Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer's disease amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases. However, the association of these markers of neurodegeneration and AD pathology with neuroinflammation has not been investigated previously. Therefore, the current study examined whether NFL and Aβ correlate with KP metabolites in elderly individuals to provide insight on the association between blood indicators of neurodegeneration and neuroinflammation.

METHODS: Correlations between KP metabolites, measured using liquid chromatography and gas chromatography coupled with mass spectrometry, and plasma NFL and Aβ concentrations, measured using …

Decrease In P3-Alcb37 And P3-Alcb40, Products Of Alcadein B Generated By G-Secretase Cleavages, In Aged Monkeys And Patients With Alzheimer’S Disease, Saori Hata, Chiori Omori, Ayano Kimura, Haruka Saito, Nobuyuki Kimura, Veer Gupta, Steve Pedrini, Eugene Hone, Pratishtha Chatterjee, Kevin Taddei, Kensaku Kasuga, Takeshi Ikeuchi, Masaaki Waragai, Masaki Nishimura, Anqi Hu, Tadashi Nakaya, Laurent Meijer, Masahiro Maeda, Tohru Yamamoto, Colin L. Masters, Chris C. Rowe, David Ames, Kazuo Yamamoto, Ralph N. Martins, Sam Gandy, Toshiharu Suzuki

Research outputs 2014 to 2021

Introduction Neuronal p3-Alcβ peptides are generated from the precursor protein Alcadein β (Alcβ) through cleavage by α- and γ-secretases of the amyloid β (Aβ) protein precursor (APP). To reveal whether p3-Alcβ is involved in Alzheimer's disease (AD) contributes for the development of novel therapy and/or drug targets. Methods We developed new sandwich enzyme-linked immunosorbent assay (sELISA) systems to quantitate levels of p3-Alcβ in the cerebrospinal fluid (CSF). Results In monkeys, CSF p3-Alcβ decreases with age, and the aging is also accompanied by decreased brain expression of Alcβ. In humans, CSF p3-Alcβ levels decrease to a greater extent in those with …

Perspectives On Ethnic And Racial Disparities In Alzheimer's Disease And Related Dementias: Update And Areas Of Immediate Need, Ganesh M. Babulal, Yakeel T. Quiroz, Benedict C. Albensi, Eider Arenaza-Urquijo, Arlene J. Astell, Claudio Babiloni, Alex Bahar-Fuchs, Joanne Bell, Gene L. Bowman, Adam M. Brickman, Gael Chetelat, Carrie Ciro, Ann D. Cohen, Peggye Dilworth-Anderson, Hiroko H. Dodge, Simone Dreux, Steven Edland, Anna Esbensen, Lisbeth Evered, Michael Ewers, Keith N. Fargo, Juan Fortea, Hector Gonzalez, Deborah R. Gustafson, Elizabeth Head, James A. Hendrix, Scott M. Hofer, Leigh A. Johnson, Roos Jutten, Kerry Kilborn, Krista L. Lanctot, Jennifer J. Manly, Ralph N. Martins, Michelle M. Mielke, Martha Clare Morris, Melissa E. Murray, Esther S. Oh, Mario A. Parra, Robert A. Rissman, Catherine M. Roe, Octavio A. Santos, Nikolaos Scarmeas, Lon S. Schneider, Nicole Schupf, Sietske Sikkes, Heather M. Snyder, Hamid R. Sohrabi, Yaakov Stern, Andre Strydom, Yi Tang, Graciela Muniz Terrera Muniz Terrera, Yaakov Stern, Andre Strydom, Yi Tang, Graciela Muniz Terrera, Charlotte Teunissen, Debora Melo Van Lent, Michael Weinborn, Linda Wesselman, Donna M. Wilcock, Henrik Zetterberg, Sid E. O’Bryant, International Society To Advance Alzheimer’S Research And Treatment, Alzheimer’S Association

Research outputs 2014 to 2021

Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a …